The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme
Abstract
The abnormal accumulation of beta-amyloid (Abeta) in the brain is an early and invariant feature in Alzheimer's disease (AD) and is believed to play a pivotal role in the etiology and pathogenesis of the disease. As such, a major focus of AD research has been the elucidation of the mechanisms responsible for the generation of Abeta. As with any peptide, however, the degree of Abeta accumulation is dependent not only on its production but also on its removal. In cell-based and in vitro models we have previously characterized endothelin-converting enzyme-1 (ECE-1) as an Abeta-degrading enzyme that appears to act intracellularly, thus limiting the amount of Abeta available for secretion. To determine the physiological significance of this activity, we analyzed Abeta levels in the brains of mice deficient for ECE-1 and a closely related enzyme, ECE-2. Significant increases in the levels of both Abeta40 and Abeta42 were found in the brains of these animals when compared with age-matched littermate controls. The increase in Abeta levels in the ECE-deficient mice provides the first direct evidence for a physiological role for both ECE-1 and ECE-2 in limiting Abeta accumulation in the brain and also provides further insight into the factors involved in Abeta clearance in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A is cleared from the brain via several clearance mechanisms, such as uptake and degradation by astro- cytes and microglia, 7,8 via A-degrading enzymes, such as neprilysin, endothelin-converting enzyme, and insulindegrading enzyme, 40 -42 and via transport by cerebral cells across the blood-brain barrier into the blood.”
From Lipoprotein Receptor-Related Protein-1 Mediates Amyloid-β-Mediated Cell Death of Cerebrovascular Cells (2007) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationCitron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease
Tanzi, R. E., Kovacs, D. M., Kim, T.-W., Moir, R. D., Guenette, S. Y., & Wasco, W. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0016 · Cited by 265
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., & Scott, R. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01743.1998 · Cited by 213
Research works printed but not linked: 39
- Iwata, 2000, Nat. Med., 6, 143, 10.1038/72237 · DOI · Paper page
- Vekrellis, 2000, J. Neurosci., 20, 1657, 10.1523/JNEUROSCI.20-05-01657.2000 · DOI · Paper page
- Chesneau, 2000, Biochem. J., 351, 509, 10.1042/bj3510509 · DOI
- Iwata, 2001, Science, 292, 1550, 10.1126/science.1059946 · DOI · Paper page
- Van Nostrand, 1999, Biochemistry, 38, 11570, 10.1021/bi990610f · DOI
- Tucker, 2000, J. Neurosci., 20, 3937, 10.1523/JNEUROSCI.20-11-03937.2000 · DOI · Paper page
- Ledesma, 2000, EMBO Rep., 1, 530, 10.1093/embo-reports/kvd107 · DOI · Paper page
- Exley, 2001, Neuroreport, 12, 2967, 10.1097/00001756-200109170-00042 · DOI
- Tucker, 2002, J. Neurosci. Res., 70, 249, 10.1002/jnr.10417 · DOI
- Hu, 2001, J. Biol. Chem., 276, 47863, 10.1074/jbc.M104068200 · DOI · Paper page
- Yamin, 1999, J. Biol. Chem., 274, 18777, 10.1074/jbc.274.26.18777 · DOI
- Qiu, 1996, J. Biol. Chem., 271, 8443, 10.1074/jbc.271.14.8443 · DOI
- Selkoe, 2001, Neuron, 32, 177, 10.1016/S0896-6273(01)00475-5 · DOI · Paper page
- Eckman, 2001, J. Biol. Chem., 276, 24540, 10.1074/jbc.M007579200 · DOI · Paper page
- Turner, 1996, Biochem. Pharmacol, 51, 91, 10.1016/0006-2952(95)02036-5 · DOI · Paper page
- Xu, 1994, Cell, 78, 473, 10.1016/0092-8674(94)90425-1 · DOI · Paper page
- Davenport, 1998, Histochem. J., 30, 359, 10.1023/A:1003236628701 · DOI
- Korth, 1999, J. Histochem. Cytochem., 47, 447, 10.1177/002215549904700403 · doi:10.1177/002215549904700403
- Barnes, 1997, J. Neurochem., 68, 570, 10.1046/j.1471-4159.1997.68020570.x · DOI
- Sluck, 1999, Neuroscience, 91, 1483, 10.1016/S0306-4522(98)00692-7 · DOI
- Nakagomi, 2000, Neuroscience, 101, 441, 10.1016/S0306-4522(00)00345-6 · DOI
- Emoto, 1995, J. Biol. Chem., 270, 15262, 10.1074/jbc.270.25.15262 · DOI · Paper page
- Yanagisawa, 2000, J. Clin. Invest., 105, 1373, 10.1172/JCI7447 · DOI · Paper page
- Yanagisawa, 1998, Development, 125, 825, 10.1242/dev.125.5.825 · DOI · Paper page
- Petanceska, 2000, Neurology, 54, 2212, 10.1212/WNL.54.12.2212 · DOI · Paper page
- Pinnix, 2001, J. Biol. Chem., 276, 481, 10.1074/jbc.M005968200 · DOI
- Borchelt, 1996, Neuron, 17, 1005, 10.1016/S0896-6273(00)80230-5 · DOI · Paper page
- De Jonghe, 1999, Hum. Mol. Genet., 8, 1529, 10.1093/hmg/8.8.1529 · DOI
- Flood, 2002, Neurobiol. Aging, 23, 335, 10.1016/S0197-4580(01)00330-X · DOI · Paper page
- Nakano, 1999, Eur. J. Neurosci., 11, 2577, 10.1046/j.1460-9568.1999.00698.x · DOI
- Hsiao, 1996, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
- Poduslo, 1999, Hum. Genet., 105, 32, 10.1007/s004399900082 · DOI
- Lorenzo, 2001, Biochim. Biophys. Acta, 1522, 46, 10.1016/S0167-4781(01)00283-4 · DOI
- Gray, 1996, Pharmacol. Ther., 72, 109, 10.1016/S0163-7258(96)00101-5 · DOI
- Loffler, 2000, J. Cardiovasc. Pharmacol., 35 Suppl. 2, S79, 10.1097/00005344-200000002-00018 · doi:10.1097/00005344-200000002-00018
- Kitas, 2002, Bioorg. Med. Chem. Lett., 12, 1727, 10.1016/S0960-894X(02)00254-8 · doi:10.1016/s0960-894x(02)00254-8
- Telemaque, 1998, J. Cardiovasc. Pharmacol., 31 Suppl. 1, S548, 10.1097/00005344-199800001-00158 · doi:10.1097/00005344-199800001-00158
- Hoang, 1997, Biochem. J., 327, 23, 10.1042/bj3270023 · DOI
- Johnson, 1999, J. Biol. Chem., 274, 4053, 10.1074/jbc.274.7.4053 · DOI
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Autophagy, amyloidogenesis and Alzheimer disease
Nixon, R. A. (2007) · Journal of Cell Science · doi:10.1242/jcs.019265 · Cited by 749
Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00787-6 · Cited by 719
Ramassamy, C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.025 · Cited by 682
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527
“Neprilysin (NEP), the insulin degrading enzyme (IDE) and endothelin-converting enzymes-1 and -2 (ECE1 and ECE2) (Eckman et al., 2001, 2003) are metalloendopeptidases particularly involved in the degradation of monomeric Aβ species (although neprilysin can also hydrolyse oligomeric forms).”
BackgroundProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380
Proteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368
“Two additional members of the M13 family of zinc metalloproteases, endothelin-converting enzymes 1 and 2 (ECE1, ECE2), are also known to be endogenous regulators of Ab (Table 1; Eckman et al. 2001, 2003).”
Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology
Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J. V., Lin, A. H., Crews, L., Tremblay, P., Mathews, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27341 · Cited by 355
Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, B., Ring, S., D’Adamio, L., Shen, J., Müller, U., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.04.008 · Cited by 348
Hemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
Self-citationβ-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
Sun, X., Chen, W.-D., & Wang, Y.-D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00221 · Cited by 323
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294
Self-citationDiverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T., Khan, M. A., Kache, R., Beard, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1235 · Cited by 284
Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E., & Selkoe, D. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63229-4 · Cited by 269
Self-citationAβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S.-I., Lu, B., Gerard, N. P., Gerard, C., Ozawa, K., & Saido, T. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4792-03.2004 · Cited by 257
Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Self-citationAmyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin
Malito, E., Hulse, R. E., & Tang, W.-J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8112-4 · Cited by 176
Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M. J., Hardy, J., Lovestone, S., & Partridge, L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001087 · Cited by 174
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo
Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407070 · Cited by 140
Wilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070050 · Cited by 138
The endocytic pathway in microglia during health, aging and Alzheimer’s disease
Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid-β
Palmer, J. C., Barker, R., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111760 · Cited by 110
Dolev, I., & Michaelson, D. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404458101 · Cited by 102
Ito, S., Ohtsuki, S., & Terasaki, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.07.006 · Cited by 99
Shinall, H., Song, E. S., & Hersh, L. B. (2005) · Biochemistry · doi:10.1021/bi050650l · Cited by 94
Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
Suire, C. N., Abdul-Hay, S. O., Sahara, T., Kang, D., Brizuela, M. K., Saftig, P., Dickson, D. W., Rosenberry, T. L., & Leissring, M. A. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00649-8 · Cited by 73
Contribution of proteases to the hallmarks of aging and to age-related neurodegeneration
Rai, M., Curley, M., Coleman, Z., & Demontis, F. (2022) · Aging Cell · doi:10.1111/acel.13603 · Cited by 72
Late Passage Cultivation Induces Aged Astrocyte Phenotypes in Rat Primary Cultured Cells
Bang, M., Gonzales, E. L., Shin, C. Y., & Kwon, K. J. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.175 · Cited by 19
Metadata
- Authors
- Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., & Eckman, C. B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 4
- Pages
- 2081-2084
- ISSN
- 0021-9258
- Cited by
- 218
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.